ARCHIVES

Nexavar Phase III Trial Fails To Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

ODAC Prefers Three-Hour Taxol Infusion. Says Data Dosage Still Uncertain

October 1, 1993

Strict Regulation Of Tobacco Products Proposed in Senate

November 24, 1989

Generic Paclitaxel Approval Withstands Court Challenge.

May 4, 2001

Preoperative Drug Combo Benefits HER-2 Breast Cancer

April 29, 2005

Malpractice Reform Bill Introduced

July 28, 1989

Texas (Galveston) Scores Nine Points Ahead Of RPMI In Organ Systems Competitio; NCAB To Decide Award

May 4, 1984